Advertisement

31 Responses

  1. Stephanie
    Stephanie July 21, 2014 at 7:14 am | | Reply

    This is EXACTLY where I think research and technology needs to focus– awesome news! One question about ViaCyte’s press releases and website. They say they want to free diabetics from “insulin dependence.”
    Ahem, I know they need catchy short hand but everyone is insulin dependent.
    If you have a chance to nudge them on their phrasing (which really is mis-leading, and suggests that only diabetics need insulin) that would be great.
    Maybe “managed insulin regimes” or, hmmm, “external insulin sources.”

  2. mcityrk
    mcityrk July 21, 2014 at 10:08 am | | Reply

    Interesting, but what is the mechanism that allows this to vary insulin release as a fuction of glucose concentration??

    Is this just ["big just!"] a basal release device??

  3. Amr
    Amr July 21, 2014 at 2:07 pm | | Reply

    Hope to have such devices as soon as possible . We have been hearing news since long time ago, whrn excepeted to have it ready to use … and if there any usage limtations , as health or age….etc.

  4. Luitpoldt
    Luitpoldt July 21, 2014 at 2:17 pm | | Reply

    Similar encapsulations of any sort of insulin-producing cell have rapidly declined in function because of problems with oxygen supply, so I’m not sure how well this will operate. Usually the encapsulation itself becomes coated by the natural responses of the recipient so that it no longer works. Also, research with encapsulated mature islets has shown that immunological effects are still produced in the rest of the body, and while embryonic tissue will have less of an immunological effect, there may still be some. Even if successful, it will still take at least a decade from now to FDA approval.

    1. John Kramarz
      John Kramarz July 23, 2014 at 4:51 am | | Reply

      I thought it would take 25 years for this to get approved, but you say only 10!
      That’s awesome!
      Thanks for the positive outlook!

  5. Michelle
    Michelle July 21, 2014 at 2:19 pm | | Reply

    Any information on affordability? Insurance coverage? No one should be left to suffer when this is available, that would be criminal.

  6. Robin
    Robin July 21, 2014 at 5:04 pm | | Reply

    I hope they will soon be including older people in trials. It is not easy to manage T1D, and with declining cognitive function so common as we age, this would be a particular boon to those no longer able to count carbs and remember to bolus. I dread entering a nursing home and being banned from eating sweets or receiving “diabetic substitutes.”

  7. kathy
    kathy July 22, 2014 at 5:31 am | | Reply

    I am so excited about this! Unless/until we learn how to regenerate our own islets, this will do the job. Having had the experience of islet cell replacement, I can say that you can’t even imagine the difference this makes in your overall health and just how you feel every day. This is what we want. I’m so proud and pleased that the JDRF is moving so decisively in this direction.

  8. Luitpoldt
    Luitpoldt July 22, 2014 at 10:52 am | | Reply

    Perhaps the primary limitation of this product, even if it is intrinsically successful, will be the supply of embryotic tissue. Since according to present estimates, there may be as many as one million type one diabetics in the United States alone, the miniscule amount of human embryotic tissue which can now be acquired yearly will make this purely an isolated display of bio-technological ingenuity, but never a realistic therapy for the vast majority of patients.

    1. Pam
      Pam July 22, 2014 at 6:28 pm | | Reply

      I am a 44 year old T1D, I was diagnosed 16 years ago. Getting older and the thought of someone else having control over my pump scares the heck out of me. This all sounded so promising right up to your last sentence, “but never a realistic therapy for the vast majority of patients”

  9. Karen
    Karen July 22, 2014 at 12:24 pm | | Reply

    I’m pretty excited about this, and also very glad to see multiple other things on the horizon as well.

    #dblogcheck

  10. David
    David July 22, 2014 at 2:05 pm | | Reply

    Cool to see another possible solution going into trials. But I don’t really understand. If this device is implanted just under the skin, won’t any insulin it releases be subject to the same slowness limitations as subcutaneously injected or pumped insulin analogs? If so, how could this possibly manage blood sugar better than we can now? Since it must necessarily respond to food reactively instead of protectively (just like the artificial pancreases, but those have some predictive/learning capability, right?…)

  11. Scott E
    Scott E July 22, 2014 at 7:59 pm | | Reply

    Best news I’ve read all day!

  12. Amber Kelley
    Amber Kelley July 23, 2014 at 11:13 am | | Reply

    This is AWSOME NEWS!!! been t1 since age 3 and am now 25 I have been a pumper for about 12 years now and the relief it would bring to not really have to worry so much about it .

  13. Lisa Brown
    Lisa Brown July 23, 2014 at 2:27 pm | | Reply

    Will there be any clinical trials? I son has been diagnosed since 2004. He 16 years old and have some fine motor delays. This makes it very difficult for him to be independent changing Pump and sensors. If you ever need somebody she is more than willing to try whatever is out there

  14. Janet
    Janet July 24, 2014 at 4:10 am | | Reply

    This is wonderful news for Type 1′s, especially all the children. I hope & pray that one day soon they’ll release the cure, until then let’s get rolling with this.
    Kudos to JDRF for their support & funding

  15. Trena Andrews
    Trena Andrews July 24, 2014 at 9:15 am | | Reply

    How can 24 year olds sign up to be in test group?

  16. Cure News: Week 7/24 | The Juvenile Diabetes Cure Alliance Blog

    [...] Although we already reported on it this week, Viacyte is officially heading to clinical trials. For those of you who don’t remember what it does, Viacyte is a small, band-aid sized [...]

  17. Brian
    Brian July 24, 2014 at 2:42 pm | | Reply

    If everyone read the website and understand the product you would get really excited. Read the WHOLE web site. First when this same device was put into mice, using Viactye encaptra system with their stem cell product, the mice glucose levels were held at human levels. In my book this is huge. Mice glucose levels are usually 400 or more. Also beta cells are encapsulation in Viactye product and blood vessel mesh with the device to provide oxygen and nutrients and remove waste all while protecting the beta cells from immune response. I think it will be here sooner than 10 years as the studies are first being done in people with establish type 1 diabetes. Which means they will know right away if it works or not.

  18. Mildred guiboche
    Mildred guiboche July 24, 2014 at 11:03 pm | | Reply

    Is this just for t1d or can any one using insulin, Drs not sure which type I am

    Because developed diabetes in mid thirties and pills did not work tried pills for three months when diagnosed and sugars where to high had to start insulin,type one is children or young adults only?

    1. Jenny
      Jenny July 25, 2014 at 10:09 pm | | Reply

      T1 means you are insulin dependent at any age. They no longer classify by age (i.e. Adult Onset, or Juvenile.) If you have been unsuccessful at managing with traditional T2 treatments then chances are you are T1.

      1. Marybeth
        Marybeth July 26, 2014 at 9:51 am | | Reply

        T1 is autoimmune diabetes and can be diagnosed at any age. I was 60 when I was diagnosed. Did you have a C-peptide testing as well as the full panel of antibodies- GADA, ICA, IA2A, IA-2A, and ZnT8. It will help define what you have. Yet to g a correct and documented dx is important for insurance coverage of the proper therapy both testing materials, as well as insulins, pumps and CGMs.

        1. Marybeth
          Marybeth July 26, 2014 at 9:57 am |

          Sorry for typo IAA
          http://www.urmc.rochester.edu/encyclopedia/content.aspx?ContentTypeID=167&ContentID=diabetes_autoantibody

          This covers the basic panel and the ZnT 8 is a more recent discovery that is found in around 60% New onset T1D’ s.

  19. Holly
    Holly July 26, 2014 at 8:46 pm | | Reply

    Pending Clinical Trials–Primary/Secondary Endpoints…the FDA could easily Fast Track any NDA…this could improve quality measure outcomes for ACO’s, reducing healthcare costs overall.

  20. Richard Price
    Richard Price July 27, 2014 at 8:44 pm | | Reply

    If it works it could revolutionize the treatment of T1D !

  21. svet
    svet July 30, 2014 at 10:47 am | | Reply

    If encapsulations become coated by the natural responses of the recipient so that they no longer work, could you please explain why animal models did not manifest such response for as long as 33 weeks, or only humans are capable of such response out of all mammals. How did those cells survive so long given the oxygen supply problem? What is your comment on the pics showing extensive growth of blood vessels around the device, providing a plentiful oxygen source and rapid distribution of insulin to the body

  22. The Case for CGM | Diabetically Speaking

    [...] experts at being stubborn and steadfast until we get what we need (*cough* bionic pancreas *cough* encapsulation *cough* smart insulin). So thankful that it appears to have finally been worked out. Ciao for now! [...]

  23. Tuesday Topic: Putting Stem Cells In My Body? | Diabetes Daily Grind

    [...] For a much more thorough breakdown of the announcement, please check out Mike’s take from DiabetesMine. [...]

  24. Dave Klingler
    Dave Klingler August 16, 2014 at 1:56 pm | | Reply

    I would characterize encapsulation as “better than nothing”.

    What I really wish would happen is that JDRF would funnel $13 million toward Denise Faustman, whose lab is the only one conducting an actual human study on complete Type I reversal. Had JDRF done that 10 years ago, Type I diabetics might now be receiving a cure at their local clinics.

    The catch is that Faustman is using a drug whose patents have long-since expired. There is no profit in Faustman’s therapy, and therefore no commercial organization is interested in funding trials.

    Instead, Type I diabetics are holding bake sales and fun runs. It’s too bad JDRF sees Faustman as a competitor for funding instead of a partner toward a larger goal, a complete cure for Type I Diabetes.

    Go read about the Faustman Lab, and if you’d like to see Type I cured, make a donation.

Leave a Reply